NCT07140809View on ClinicalTrials.gov

a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 9, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

August 1, 2026

Conditions
Hypertriglyceridemia
Interventions
BIOLOGICAL

JMT202 injection

Subcutaneous injection

OTHER

Placebo

Matching Placebo

All Listed Sponsors
lead

Shanghai JMT-Bio Inc.

INDUSTRY

NCT07140809 - a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia | Biotech Hunter | Biotech Hunter